Pedro Folegatti

MD, DTM&H, MSc

Clinical Research Fellow

Vaccine Clinical Trials

I am a Clinical Research Fellow and DPhil candidate on the Influenza and Emerging Pathogens vaccine clinical development programmes at The Jenner Institute - University of Oxford

My research focuses on the use of the simian adenovirus vector ChAdOx1 as a platform technology for vaccine development against emerging pathogens.

I am an investigator and the lead clinician for the COVID-19, MERS-CoV, Chikungunya, Zika, and Rift Valley Fever vaccine clinical trials

I trained as an Infectious Diseases physician in Brazil and hold a Masters degree in Public Health from the London School of Hygiene and Tropical Medicine.

Recent publications

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article

Barrett JR. et al, (2020), Nature Medicine
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article

Ewer KJ. et al, (2020), Nature Medicine
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article

Voysey M. et al, (2020), The Lancet
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)
Journal article

Folegatti PM. et al, (2020), LANCET, 396, 466 - 466

More publications